DR. LEE ROY MORGAN, M.D.
Osteopathic Medicine at Topaz St, New Orleans, LA

2013014, Jun 13, 2013

Jul 3, 2012

13/541522

Lee R. MORGAN - New Orleans LA, US

A61K 31/664, A61K 45/06, C07F 9/22

4241301, 562 10, 514 76, 424 941, 424649, 514 209, 514 34, 424 946

The present disclosure relates to salts and compositions of isophosphoramide mustard and isophosphoramide mustard analogs. In one embodiment the salts can be represented by the formula I:(I) wherein Arepresents an ammonium species selected from the protonated (conjugate acid) or quaternary forms of aliphatic amines and aromatic amines, including basic amino acids, heterocyclic amines, substituted and unsubstituted pyridines, guanidines and amidines; and X and Y independently represent leaving groups. Also disclosed herein are methods for making such compounds and formulating pharmaceutical compositions thereof. Methods for administering the disclosed compounds to subjects, particularly to treat hyperproliferative disorders, also are disclosed.

4827016, May 2, 1989

Jul 20, 1987

7/075579

Lee R. Morgan - New Orleans LA

C07C14943, C07C14941

560 16

Dermal inflammations which are induced and propagated by leukotrienes are treated by topically applying to the inflamed dermis the following compound: ##STR1## wherein R. sup. 3 is H or a thiol; n is 1 to 12; p is 0 to 12; X is a substituted carbonyl, such as an ester or a carboxylic acid; and Y is an aliphatic or branched hydrocarbon, aromatic ring, carbonyl or substituted amide.

8124596, Feb 28, 2012

Dec 12, 2006

12/085789

Lee Roy Morgan - New Orleans LA, US

Dekk-Tec, Inc. - New Orleans LA

A01N 45/00, A61K 31/56, C07D 211/68, C07J 9/00

514169, 546285, 552540

This disclosure concerns novel demethylpenclomedine analogs. Also disclosed are pharmaceutical compositions and methods for using such compositions to treat hyperproliferative disorders. In one embodiment the analogs are represented by the formula (1).

5183455, Feb 2, 1993

Nov 5, 1990

7/609437

Michael H. Hayman - New Orleans LA
Lee R. Morgan - New Orleans LA
Samuel F. Liprie - Lake Charles LA

Omnitron International, Inc. - Houston TX

A61M 3604

600 7

Apparatus for in situ radiotherapy has a flexible catheter having a proximal end for receiving a radioisotope and a distal end for positioning the flexible catheter within a patient to be treated. An anchor, which is permanently connectable to tissues deep inside the patient, has a sealing collar connected to it which seals the distal end of the catheter. The catheter also includes a plug near the distal end which seals the distal end in addititon to the seal provided by the sealing collar. The anchor has a penetration point connected to it to assist a surgeon in implanting the catheter within a tumor. A threaded fastener on the anchor is screwed into the catheter. The flexible catheter can be released remotely from the anchor by unscrewing it. A suture eye is connected to the anchor. The suture eye may be sutured to healthy tissue within the patient when the apparatus is implanted to secure the anchor to the patient.

2007004, Mar 1, 2007

Feb 27, 2004

10/547223

Lee Roy Morgan - New Orleans LA, US

A61K 38/16, A61K 31/7034, A61K 31/655, A61K 31/445, A61K 31/185, A61K 31/195, A61K 31/15

514002000, 514317000, 514459000, 514432000, 514639000, 514114000, 514553000, 514561000, 514151000, 514023000

A method and device are disclosed for monitoring and/or altering an immune function. The method uses a resonance modulating compound as a coupling agent that is capable of interacting with the immune system to monitor or stimulate immune function. The resonance modulator has electromagnetic properties that attract immune cells to a target area to which the resonance modulating agent has been applied. Electromagnetic properties (such as a voltage amplitude) of the target region are altered in the presence of the resonance modulator, and serve as an indicator of immune function. An external stimulus (such as an applied electromagnetic field) can also be applied to the resonance modulator to enhance its immune stimulating and attractant properties. Particular examples of the resonance modulator are aryl hydrazones. The described aryl nitrohydrazones have the ability to interact with populations of cells with emergent behavioral characteristics associated with chemical, biological and radiation changes and injury. The disclosure also provides numerous other examples of resonance modulating agents, and provides attributes of these agents and assays for identifying additional resonance modulating agents.

4916711, Apr 10, 1990

Sep 29, 1988

7/251188

Joseph H. Boyer - New Orleans LA
Lee R. Morgan - New Orleans LA

H01S 320

372 53

A new group of fluorescent organic materials having a variety of uses are described. They are especially useful as dye compounds in dye laser systems, and as photochemical agents in the treatment of diseased tissues using photodynamic therapy techniques. The materials involve a tri-cyclic compound having the following structure: ##STR1## In this structure, R. sub. 1 -R. sub. 21 represent a variety of organic and inorganic groups.

4732904, Mar 22, 1988

Sep 16, 1985

6/776424

Lee R. Morgan - New Orleans LA

C07D21353, C07D21365, C07C10914, A61K 3144

514357

Azido-, 4-nitro and 2,4-dinitrophenylhydrazones as well as 4,4'-dihydroxybenzophenone-hydrazone and other hydrazones are disclosed which have antiestrogenic activity useful in treating estrogen-requiring tumor cells. The described hydrazones bind to estrogen receptors in the cytoplasm of tumor cells. The azido-, 4-nitro- and 2,4-dinitro-phenyl branches of the molecules appear to bind to the receptors and prevent translocation of estrogenic information into the nucleus, thereby blocking the synthesis of necessary macromolecules such as proteins. Absence of geometric isomerization from antiestrogenic to estrogenic forms of the drug minimizes estrogenic side-effects.

4724239, Feb 9, 1988

Sep 16, 1985

6/776579

Lee R. Morgan - New Orleans LA

A61K 31195

514563

A method of treating chemical ulcers caused by leukotriene production, the method comprising the step of applying to the ulcer a compound that interferes with leukotriene production, the compound being selected from the group consisting of N,N'-diacetylcystine, N-acetylhomocysteine and N-acetylcysteine.